Absence of anti-RBD antibodies in SARS-CoV-2 infected or naive individuals prior to vaccination with CoronaVac leads to short protection of only four months duration

• Autor(a) principal: Oliveira, Camille F. de
• Data de Publicação: 2022
• Outros Autores: Franco Neto, Walter Felix, Silva, Carla P. da, Ribeiro, Ana Claudia Santos, Martins, Lívia Caricio, Sousa, Alana W. de, Freitas, Maria N. O, Chiang, Jannifer Oliveira, Silva, Franko A, Santos, Eder B. dos, Medeiros, Daniele Barbosa de Almeida, Pinheiro, Gleiciane S, Brandão, Gleiciane F, Carvalho, Valéria Lima, Azevedo, Raimunda do Socorro da Silva, Vasconcelos, Pedro Fernando da Costa, Costa, Igor Brasil, Costa, Iran Barros, Santos, Mirleide Cordeiro dos, Soares, Luana da Silva, Bedran, Rayssa L. S, Ferreira, James L, Amarilla, Alberto Anastacio, Modhiran, Naphak, McMillan, Christopher L. D, Freney, Morgan E, Muller, David A, Watterson, Daniel, Casseb, Lívia Medeiros Neves, Henriques, Daniele Freitas
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
• Texto Completo: http://patua.iec.gov.br//handle/iec/4555
• topic: SARS-CoV-2 / patogenicidade; COVID-19; Anticorpos / análise; Vacinas contra COVID-19 / análise; Teste Sorológico para COVID-19; CoronaVac

Abstract: The COVID-19 pandemic is the biggest public health threat facing the world today. Multiple vaccines have been approved; however, the emergence of viral variants such as the recent Omicron raises the possibility of booster doses to achieve adequate protection. In Brazil, the CoronaVac (Sinovac, Beijing, China) vaccine was used; however, it is important to assess the immune response to this vaccine over time. This study aimed to monitor the anti-SARS-CoV-2 antibody responses in those immunized with CoronaVac and SARS-CoV-2 infected individuals. Samples were collected between August 2020 and August 2021. Within the vaccinated cohort, some individuals had a history of infection by SARS-CoV-2 prior to immunization, while others did not. We analyzed RBD-specific and neutralizing-antibodies. Anti-RBD antibodies were detected in both cohorts, with a peak between 45–90 days post infection or vaccination, followed by a steady decline over time. In those with a previous history of COVID-19, a higher, longer, more persistent response was observed. This trend was mirrored in the neutralization assays, where infection, followed by immunization, resulted in higher, longer lasting responses which were conditioned on the presence of levels of RBD antibodies right before the vaccination. This supports the necessity of booster doses of CoronaVac in due course to prevent serious disease.